30 closest matches · ranked by relevance
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants
Recurrent Childhood Anaplastic Astrocytoma · Recurrent Childhood Brain Stem Glioma · Recurrent Childhood Ependymoma
Primary: Relative Phosphorylation of ERBB2 (Molecular Biology Objective) — .21; .50 ratio
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Sarcoma
Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Recurrent and Refractory Solid Tumors
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus — 11 milligram per square meter (mg/m^2)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Childhood Cerebellar Anaplastic Astrocytoma · Childhood Cerebral Anaplastic Astrocytoma · Childhood Cerebral Astrocytoma
Primary: Sustained Objective Response Rate — 0; 0 percentage of patients
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Neuroblastoma
Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants
Relapsed/Refractory Rhabdomyosarcoma · Non-rhabdomyosarcoma Soft Tissue Sarcoma · Ewing Sarcoma
Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Embryonal Rhabdomyosarcoma
Primary: Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment — 0.9390 Proportion of Participants
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Anaplastic Ependymoma · Brain Ependymoma · Cellular Ependymoma
Primary: Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or…
Metastatic Medulloblastoma · High Risk Supratentorial PNET · Metastatic PNET
Primary: Event-free Survival — 7 Participants
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…